Dow Jones
32.637,19 +516,91 (+1,61%) Nasdaq
11.740,65 +305,91 (+2,68%) Nikkei 225
26.777,05 +172,21 (+0,65%) EUR/USD
1,0756 +0,0023 (+0,22%) BTC-EUR
26.963,74 -863,57 (-3,10%) CMC Crypto 200
626,35 -34,79 (-5,26%)
Resmed Inc. (RME.SG)
| Chiusura precedente | 181,42 |
| Aperto | 183,26 |
| Denaro | 188,44 x 30000 |
| Lettera | 189,12 x 30000 |
| Min-Max giorno | 183,26 - 183,26 |
| Intervallo di 52 settimane | 166,05 - 254,60 |
| Volume | |
| Media Volume | 88 |
| Capitalizzazione | N/D |
| Beta (5 anni mensile) | N/D |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | N/D |
| Prossima data utili | N/D |
| Rendimento e dividendo (forward) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
- GlobeNewswire
ResMed Announces Participation in the 38th Annual Bernstein Strategic Decisions Conference
SAN DIEGO, May 25, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chief executive officer, will participate in a fireside chat at the Bernstein Strategic Decisions Conference on Wednesday, June 1, 2022, beginning at approximately 1:30 p.m. (Eastern Daylight Time) at the New York Hilton Midtown in New York City. More information about this event, including a live webcast, may be accessed by visiting http://investor.resmed.com. The webcast replay will be availa
- GlobeNewswire
Even 2 Hours of PAP Therapy per Night Benefits Sleep Apnea Sufferers: ResMed Study
2–3 hours of nightly PAP use shows health benefits at 3 months, 1 year, and 2 yearsHealth benefits significantly increase by use hour/night, up to 7 hours SAN FRANCISCO, May 18, 2022 (GLOBE NEWSWIRE) -- Sleep apnea sufferers can gain health benefits from PAP (positive airway pressure) treatment in as little as two hours per night, according to a study led by ResMed (NYSE: RMD, ASX: RMD) and presented at the American Thoracic Society’s annual International Conference. The retrospective, observati
- GlobeNewswire
ResMed Announces Leadership Change
SAN DIEGO, May 05, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced that Jim Hollingshead, President, Sleep and Respiratory Care, has informed ResMed that he has accepted a new position and is leaving the company, effective immediately. Rob Douglas, President and Chief Operating Officer, has been appointed interim President, Sleep and Respiratory Care. “I’d like to thank Jim for his 12 years of service and valuable contributions to ResMed,” said Mick Farrell, ResMed CEO. “Ji
